Moleculin Biotech's Net Loss Widens to $49.1M Amid Warrant Issuances

TL;DR

**MBRX is burning cash and diluting shareholders to fund its pipeline, making it a high-risk bet on Annamycin's Phase 3 success.**

AI Summary

Moleculin Biotech, Inc. (MBRX) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $49.112 million, a substantial rise from $19.464 million in the same period of 2024. This increase was primarily driven by a $30.962 million loss on the issuance of warrant liabilities in 2025, compared to none in 2024. Research and development expenses decreased to $10.774 million from $13.274 million year-over-year, while general and administrative expenses slightly increased to $6.715 million from $6.629 million. The company's cash and cash equivalents improved to $6.703 million as of September 30, 2025, up from $4.278 million at December 31, 2024, largely due to $19.797 million in net cash provided by financing activities. However, total stockholders' equity shifted to a deficit of $26.920 million from a positive $11.208 million, mainly due to the increased accumulated deficit. MBRX is actively conducting a pivotal Phase 3 trial for Annamycin in relapsed/refractory acute myeloid leukemia (AML) and faces Nasdaq listing compliance issues regarding minimum stockholders' equity and bid price.

Why It Matters

This filing reveals a critical financial inflection point for Moleculin Biotech. The substantial increase in net loss, primarily due to warrant liabilities, signals aggressive financing activities to fund its clinical trials, particularly the pivotal Phase 3 for Annamycin. For investors, this highlights dilution risk and the company's reliance on capital markets. Employees and customers are impacted by the long-term viability of the company, which is tied to successful drug development and financial stability. In the competitive biotech landscape, MBRX's ability to navigate these financial challenges while advancing its drug pipeline, especially against larger pharmaceutical players, will determine its future market position.

Risk Assessment

Risk Level: high — The company reported a net loss of $49.112 million for the nine months ended September 30, 2025, a significant increase from $19.464 million in the prior year, primarily due to a $30.962 million loss on issuance of warrant liabilities. Furthermore, total stockholders' equity has plummeted to a deficit of $26.920 million from a positive $11.208 million at December 31, 2024, and the company is non-compliant with Nasdaq's minimum $2.5 million stockholders' equity rule and the $1.00 bid price rule, indicating severe financial distress and potential delisting.

Analyst Insight

Investors should exercise extreme caution and consider the high risk associated with MBRX. Given the significant net loss, negative stockholders' equity, and Nasdaq compliance issues, a wait-and-see approach is advisable until there is clear evidence of financial stabilization or significant positive clinical trial results for Annamycin. Current shareholders should evaluate their risk tolerance and potential for further dilution or delisting.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$20.353M

total Debt

$47.273M

net Income

-$49.112M

eps

-$2.36

gross Margin

N/A

cash Position

$6.703M

revenue Growth

N/A

Key Numbers

• $49.112M — Net Loss (for the nine months ended September 30, 2025, up from $19.464M in 2024)
• $30.962M — Loss on issuance of warrant liabilities (primary driver of increased net loss in 2025)
• $26.920M — Total Stockholders' Equity (Deficit) (as of September 30, 2025, a significant decrease from $11.208M at Dec 31, 2024)
• $6.703M — Cash and Cash Equivalents (as of September 30, 2025, up from $4.278M at Dec 31, 2024)
• $19.797M — Net cash provided by financing activities (for the nine months ended September 30, 2025)
• $10.774M — Research and development expenses (for the nine months ended September 30, 2025, down from $13.274M in 2024)
• 50,910,476 — Common shares outstanding (as of November 7, 2025)
• $0.68 — Net loss per common share (for the three months ended September 30, 2025)

Key Players & Entities

• Moleculin Biotech, Inc. (company) — clinical-stage pharmaceutical company
• Nasdaq Stock Market LLC (regulator) — notified company of listing rule non-compliance
• Annamycin (drug) — lead molecule in pivotal Phase 3 trial for R/R AML
• University of Texas MD Anderson Cancer Center (company) — source of licensed discoveries for MBI's technologies
• Animal Life Sciences, Inc. (company) — sublicensee of MBI's technologies for non-human use
• Cytarabine (drug) — combination therapy with Annamycin for AML
• WP1066 (drug) — investigated in Phase 1B/2 clinical trial for glioblastoma
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Significant Increase in Net Loss Driven by Warrant Liabilities [high — financial]: The company reported a net loss of $49.112 million for the nine months ended September 30, 2025, a substantial increase from $19.464 million in the prior year. This was primarily due to a $30.962 million loss on the issuance of warrant liabilities in 2025, a factor not present in 2024. This highlights the significant financial impact of equity-linked instruments.
• Deterioration of Stockholders' Equity [high — financial]: Total stockholders' equity shifted to a deficit of $26.920 million as of September 30, 2025, from a positive $11.208 million at December 31, 2024. This deterioration is largely attributed to an increased accumulated deficit, signaling a weakening equity position.
• Nasdaq Listing Compliance Issues [high — regulatory]: Moleculin Biotech faces potential delisting from Nasdaq due to non-compliance with minimum stockholders' equity and minimum bid price requirements. This poses a significant risk to the company's ability to access public markets and maintain investor confidence.
• Dependence on Clinical Trial Success [high — operational]: The company's primary focus is the pivotal Phase 3 trial for Annamycin in relapsed/refractory acute myeloid leukemia (AML). The success or failure of this trial is critical to the company's future prospects and valuation, representing a concentrated operational risk.
• Negative Operating Cash Flow [medium — financial]: Despite an increase in cash from financing activities ($19.797 million), the company's operations resulted in a significant net loss. The substantial accumulated deficit of $221.556 million indicates a history of unprofitability, requiring continuous funding to sustain operations.
• High Warrant Liability [medium — financial]: The balance sheet shows a significant warrant liability of $41.333 million as of September 30, 2025. This liability, along with the associated issuance loss, represents a substantial financial obligation and a source of volatility.

Industry Context

Moleculin Biotech operates in the highly competitive biotechnology sector, focusing on oncology drug development. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success is heavily dependent on clinical trial outcomes and the ability to secure substantial funding to advance pipeline candidates through development and commercialization.

Regulatory Implications

The company faces significant regulatory risks related to its Nasdaq listing status. Failure to regain compliance with minimum stockholders' equity and bid price requirements could lead to delisting, severely impacting liquidity and investor confidence. Furthermore, the success of its Annamycin Phase 3 trial is paramount for potential FDA approval.

What Investors Should Do

1. Monitor Nasdaq compliance status closely.
2. Evaluate the progress and interim results of the Annamycin Phase 3 trial.
3. Assess the company's cash burn rate and future financing needs.
4. Analyze the impact of warrant liabilities on future financial performance.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a net loss of $49.112 million, significantly impacted by a $30.962 million loss on warrant liabilities. Stockholders' equity moved to a deficit of $26.920 million.
• 2024-12-31: As of December 31, 2024 — Reported positive stockholders' equity of $11.208 million and a smaller net loss for the comparable period in 2024 ($19.464 million).
• 2025-11-07: Common shares outstanding — 50,910,476 shares outstanding as of this date, indicating a significant increase from prior periods, likely due to financing activities.

Glossary

Warrant liability

A financial instrument that gives the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. These are often issued as part of a financing deal and their fair value can fluctuate, leading to gains or losses. (A significant $41.333 million warrant liability and a $30.962 million loss on its issuance heavily impacted MBRX's net loss in the current period.)

Accumulated deficit

The cumulative net losses of a company since its inception that have not been offset by net income. It represents the total losses incurred over time. (MBRX's accumulated deficit grew to $221.556 million, contributing to the negative stockholders' equity and highlighting a history of unprofitability.)

Pivotal Phase 3 trial

The final stage of clinical testing for a new drug, designed to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely. Success in a Phase 3 trial is typically required for regulatory approval. (MBRX is undergoing a pivotal Phase 3 trial for Annamycin, which is critical for the company's future revenue generation and valuation.)

Stockholders' equity (deficit)

The net worth of a company, calculated as total assets minus total liabilities. A deficit means that liabilities exceed assets, indicating negative net worth. (MBRX's shift to a $26.920 million deficit in stockholders' equity is a major concern, impacting its financial health and Nasdaq compliance.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Moleculin Biotech has experienced a dramatic increase in net loss, soaring from $19.464 million to $49.112 million, largely driven by a $30.962 million loss on warrant liabilities. While R&D expenses decreased, the company's financial health has weakened, evidenced by a shift from positive stockholders' equity of $11.208 million to a deficit of $26.920 million. New risks have emerged, notably the Nasdaq listing compliance issues, which were not a concern in the previous reporting period.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share MBRX The NASDAQ Stock Mar
• $2.5 million — that the Company maintain a minimum of $2.5 million in stockholders' equity, and that the C
• $1.00 — mmon stock had closed below the minimum $1.00 per share requirement for continued inc

Filing Documents

• mbrx20250930_10q.htm (10-Q) — 1324KB
• ex_885635.htm (EX-18.1) — 9KB
• ex_856599.htm (EX-31.1) — 13KB
• ex_856600.htm (EX-31.2) — 13KB
• ex_856601.htm (EX-32.1) — 7KB
• ex_856602.htm (EX-32.2) — 7KB
• mo1.jpg (GRAPHIC) — 12KB
• mo2.jpg (GRAPHIC) — 7KB
• moleculin.jpg (GRAPHIC) — 8KB
• moleculinnewlogoresized.jpg (GRAPHIC) — 8KB
• 0001437749-25-034839.txt ( ) — 6888KB
• mbrx-20250930.xsd (EX-101.SCH) — 52KB
• mbrx-20250930_cal.xml (EX-101.CAL) — 28KB
• mbrx-20250930_def.xml (EX-101.DEF) — 316KB
• mbrx-20250930_lab.xml (EX-101.LAB) — 287KB
• mbrx-20250930_pre.xml (EX-101.PRE) — 340KB
• mbrx20250930_10q_htm.xml (XML) — 1517KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 3 Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity (Deficit) for the Nine Months Ended September 30, 2025 and 2024 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 19 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 31 Item 4.

Controls and Procedures

Controls and Procedures 31

– OTHER INFORMATION

PART II – OTHER INFORMATION 31 Item 1.

Legal Proceedings

Legal Proceedings 31 Item 1A.

Risk Factors

Risk Factors 31 Item 2. Unregistered sales of Equity Securities and Uses of Proceeds 33 Item 3. Defaults Upon Senior Securities 33 Item 4. Mine Safety Disclosures 33 Item 5. Other Information 33 Item 6. Exhibits 34

Signatures

Signatures 35 2 Table of Contents PART 1 FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Moleculin Biotech, Inc. Condensed Consolidated Balance Sheets (in thousands, except for share and per share data) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash and cash equivalents $ 6,703 $ 4,278 Prepaid expenses and other current assets 1,182 916 Total current assets 7,885 5,194 Intangible assets 11,148 11,148 Other non-current assets 900 — Operating lease right-of-use asset 343 424 Furniture and equipment, net 77 159 Total assets $ 20,353 $ 16,925 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 2,116 $ 2,030 Accrued expenses and other current liabilities 3,566 3,329 Total current liabilities 5,682 5,359 Operating lease liability - long-term, net of current portion 258 358 Warrant liability 41,333 — Total liabilities 47,273 5,717 Commitments and contingencies (Note 7) Stockholders' equity (deficit) Preferred stock, $ 0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding — — Common stock, $ 0.001 par value; 500,000,000 shares authorized; 49,498,576 and 3,378,895 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 49 3 Additional paid-in capital 194,631 183,690 Accumulated other comprehensive loss ( 44 ) ( 41 ) Accumulated deficit ( 221,556 ) ( 172,444 ) Total stockholders' equity (deficit) ( 26,920 ) 11,208 Total liabilities and stockholders' equity $ 20,353 $ 16,925 See accompanying notes to condensed consolidated financial statements. 3 Table of Contents Moleculin Biotech, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Revenues $ — $ — $ — $ — Operating expenses: Research and development 3,738 4,932 10,774 13,274

View Full Filing

View this 10-Q filing on SEC EDGAR